Bionic skin technology provides advanced tactile recognition and visualization capabilities

Ab­b­Vie is ac­quir­ing au­toim­mune start­up Lan­dos Bio­phar­ma, ac­cord­ing to a Mon­day an­nounce­ment, aim­ing to cap­i­tal­ize on an IBD drug that re­cent­ly en­tered Phase 2. The

Spanish-headquartered Minoryx Therapeutics says the U.S. Food and Drug Administration (FDA) has approved its phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat